

INVITATION

FRIDAY
11
MARCH

18:00–18:30
CET

MALLINCKRODT SYMPOSIUM AT **7th SYSTEMIC SCLEROSIS** **WORLD CONGRESS**

VIRTUAL MEETING

This information is not intended for healthcare professionals in the US and Canada

AGENDA

18:00 – 18:30

The proposed mechanism of action and role of ECP in treating Systemic Sclerosis



Robert Gniadecki, MD, PhD, DMSci

Professor and Director, Faculty of Medicine and Dentistry
Department of Medicine, Division of Dermatology
University of Alberta

ECP: Extracorporeal Photopheresis

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company.

[Privacy policy](#)

Follow the Therakos Institute on LinkedIn



For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.
© 2022 Mallinckrodt. Item code: EU-2200015. Date of preparation: January 2022.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.